TY - JOUR T1 - Kinetics of SARS-CoV-2 anti-s IgG after BNT162b2 vaccination JF - medRxiv DO - 10.1101/2021.03.03.21252844 SP - 2021.03.03.21252844 AU - Daniel Grupel AU - Sivan Gazit AU - Licita Schreiber AU - Varda Nadler AU - Tamar Wolf AU - Rachel Lazar AU - Lia Supino-Rosin AU - Galit Perez AU - Asaf Peretz AU - Amir Ben Tov AU - Miri Mizrahi-Reuveni AU - Gabriel Chodick AU - Tal Patalon Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/05/2021.03.03.21252844.abstract N2 - Deployment of the BNT162b2 mRNA Covid-19 Vaccine in Israel began in December 2020.This is a retrospective analysis of serological data, describing SARS-CoV-2 anti-S IgG kinetics in 116 Israeli healthcare workers administrated the BNT162b2 vaccine.Seroconversion occurred by day 14 in all individuals, with IgG levels peaking approximately 30 days post inoculation.This study demonstrated the kinetics of the antibody response post vaccination with BNT162b2. The robustness of seroconversion was observed, alongside a statistically significant difference in IgG levels between employees over and younger 50 years of afge. Further research is required in order to examine the antibody kinetics overtime, as well as whether the age-dependent difference persists.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received for this studyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Maccabi Health Services IRB, IsraelAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available with the corresponding author ER -